Clinical Trial Update: Fruquintinib and SeRplulimab: Opening New Frontiers in Treating Non-clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Fruquintinib plus SeRplulimab for non-clear renal cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)
• Serplulimab (serplulimab)

Snippet

Sponsor: RenJi Hospital | Conditions: Non-clear Renal Cell Carcinoma | Phase 2 | Status: RECRUITING